SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Part of paid clinical trials in San Francisco, California.
- Sponsor
- SAb Biotherapeutics, Inc.
- Study ID
- NCT07187531
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 40 Years
- Healthy Volunteers
- Not accepted
Interventions
- High Dose SAB-142 — DRUGHigh Dose SAB-142
- Low Dose SAB-142 — DRUGLow Dose SAB-142
- Placebo — OTHERPlacebo
Study Details
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
Key Dates
- Start date
- Nov 25, 2025
- Status verified
- May 2026
- Primary completion
- Nov 30, 2027
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 159 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: High Dose SAB-142Part A: Open-label, parallel arm study. Part B: Double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised.
- Experimental: Low Dose SAB-142Part A: Open-label, parallel arm study. Part B: Double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised.
- Placebo Comparator: PlaceboPart B: This is a double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised.
Primary Outcome Measure
Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) [ Time Frame: From dose administration through Week 4 ]
Central Contacts
- Senior Manager Clinical Operations1-844-763-1890
Locations (23)
Find similar trials in San Francisco, CA
By condition
By specialty
By research site
University of California San Francisco Benioff Children's Hospital· San Francisco, CASan Jose Clinical Trials, LLC· San Jose, CAUniversity of Colorado - Barbara Davis Center for Diabetes· Aurora, COUniversity of Florida College of Medicine· Gainesville, FLUniversity of Miami - Gables One Tower· Miami, FLChildren's Healthcare of Atlanta (CHOA) - Center for Advanced Pediatrics· Atlanta, GA
Related Studies
- Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1EARLY_PHASE1 · Recruiting · Augusta University · Augusta, Georgia
- General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care DeliveryRecruiting · Sanford Health · Bemidji, Minnesota
- The T1D Exchange RegistryRecruiting · T1D Exchange, United States · Boston, Massachusetts
- Combined Antibody Screening for Celiac and Diabetes EvaluationEnrolling By Invitation · Pacific Northwest Research Institute · Seattle, Washington